Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Adult
Aged
Blood Glucose
/ drug effects
Diabetes Mellitus, Type 2
/ blood
Drug Therapy, Combination
Female
Glucosides
/ administration & dosage
Glycated Hemoglobin
/ drug effects
Humans
Hypoglycemic Agents
/ administration & dosage
Intra-Abdominal Fat
/ drug effects
Japan
Male
Metformin
/ administration & dosage
Middle Aged
Prospective Studies
Single-Blind Method
Sitagliptin Phosphate
/ administration & dosage
Thiophenes
/ administration & dosage
Treatment Outcome
insulin sensitivity
ipragliflozin
metformin
sitagliptin
visceral fat
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
11
01
2019
revised:
14
04
2019
accepted:
14
04
2019
pubmed:
18
4
2019
medline:
17
9
2020
entrez:
18
4
2019
Statut:
ppublish
Résumé
A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study was conducted to evaluate the efficacy of treatment with ipragliflozin (sodium-dependent glucose transporter-2 inhibitor) versus metformin for visceral fat reduction and glycaemic control among Japanese patients with type 2 diabetes treated with sitagliptin, HbA1c levels of 7%-10%, and body mass index (BMI) ≥ 22 kg/m
Identifiants
pubmed: 30993861
doi: 10.1111/dom.13750
pmc: PMC6767075
doi:
Substances chimiques
Blood Glucose
0
Glucosides
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Thiophenes
0
hemoglobin A1c protein, human
0
ipragliflozin
3N2N8OOR7X
Metformin
9100L32L2N
Sitagliptin Phosphate
TS63EW8X6F
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1990-1995Informations de copyright
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Am J Med. 2017 Oct;130(10):1170-1176
pubmed: 28396226
Diabetes Obes Metab. 2018 Jun;20(6):1427-1434
pubmed: 29405540
Abdom Radiol (NY). 2019 May;44(5):1907-1916
pubmed: 30694368
Diabetes Care. 2013 Sep;36(9):2756-62
pubmed: 23579178
Diabetes Obes Metab. 2019 Aug;21(8):1990-1995
pubmed: 30993861
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes. 2016 Jul;65(7):2032-8
pubmed: 27207551
Lancet. 2004 Jan 17;363(9404):248-9
pubmed: 14738815
Adipocyte. 2018;7(2):121-128
pubmed: 29376471
Clin Chim Acta. 2007 Sep;384(1-2):118-23
pubmed: 17651713
Diabetes Obes Metab. 2014 Dec;16(12):1230-8
pubmed: 25132119
Diabetes Care. 2007 Sep;30(9):2392-4
pubmed: 17563343
Diabetes Care. 2015 Oct;38(10):1858-67
pubmed: 26251408
BMJ Open. 2017 May 9;7(5):e015766
pubmed: 28490565
Diabetes Obes Metab. 2014 Feb;16(2):159-69
pubmed: 23906445
Diabetes Obes Metab. 2015 Mar;17(3):294-303
pubmed: 25495720
J Diabetes Investig. 2016 Apr;7 Suppl 1:102-9
pubmed: 27186364
Med Arch. 2013;67(5):365-7
pubmed: 24601174
Proc Natl Acad Sci U S A. 1978 Sep;75(9):4519-23
pubmed: 212757
Diabetes Obes Metab. 2007 May;9(3):282-9
pubmed: 17391153
J Clin Invest. 2004 Jun;113(11):1582-8
pubmed: 15173884